Kelso E J, Geraghty R F, McDermott B J, Trimble E R, Nicholls D P, Silke B
Department of Therapeutics and Pharmacology, Queen's University, Belfast, Northern Ireland.
Mol Cell Biochem. 1996;157(1-2):149-55. doi: 10.1007/BF00227893.
Endothelin (ET-1) is found at elevated concentrations in the plasma of patients with heart failure and in animal models of cardiomyopathy. The peptide is a potent positive inotropic agent, the effects of which are mediated by increases in cytosolic Ca2+ in cardiomyocytes. The object of this study was to investigate at the cellular level, the actions of ET-1 on contractile function and on Ca2+ currents in heart-failed ventricular myocardium. Male New Zealand White rabbits (8 wks) were treated with twice weekly injections of epirubicin (4 mg/kg/wk, n = 7) or with saline (n = 7) for 6 wks, followed by a washout period of 2 wks. Ventricular cardiomyocytes were isolated from rabbit hearts using Langendorff perfusion with collagenase; contractile function was examined using a video microscopy method, and L-type Ca2+ currents were recorded using a whole-cell patch-clamp technique. ET-1 produced a concentration-dependent increase in contractile response (% increase from basal value) to a maximum at 1 nM ET-1 of 69 +/- 11% (mean +/- S.D.) in control cardiomyocytes and 33 +/- 6% in heart-failed cells. However, there was no significant change in the EC50 obtained with ET-1 for healthy (0.31 +/- 0.1 nM) and for failed cardiomyocytes (0.24 +/- 0.1 nM). The effects of ET-1 on L-type Ca2+ channels were similar with a peak amplitude at 1 nM ET-1 of -3.26 +/- 0.8 nA in control cardiomyocytes and -3.32 +/- 0.9 nA in heart-failed cells. The attenuation of the contractile response to ET-1 in heart-failed cells may reflect a desensitization of ET receptors as a consequence of elevated circulating levels of ET and was not reflected by alteration of transmembrane Ca2+ conductance. It is probable, therefore, that multiple signalling pathways are involved in the actions of ET on ventricular myocardium.
内皮素(ET-1)在心力衰竭患者的血浆以及心肌病动物模型中浓度升高。该肽是一种强效正性肌力药物,其作用通过心肌细胞胞质Ca2+浓度升高介导。本研究的目的是在细胞水平上研究ET-1对心力衰竭心室心肌收缩功能和Ca2+电流的作用。雄性新西兰白兔(8周龄)每周两次注射表柔比星(4mg/kg/周,n = 7)或生理盐水(n = 7),持续6周,随后有2周的洗脱期。使用胶原酶通过Langendorff灌注从兔心脏分离心室心肌细胞;使用视频显微镜方法检查收缩功能,并使用全细胞膜片钳技术记录L型Ca2+电流。ET-1使对照心肌细胞对收缩反应(相对于基础值的增加百分比)呈浓度依赖性增加,在1nM ET-1时达到最大值,为69±11%(平均值±标准差),在心力衰竭细胞中为33±6%。然而,ET-1对健康心肌细胞(0.31±0.1 nM)和心力衰竭心肌细胞(0.24±0.1 nM)的半数有效浓度(EC50)没有显著变化。ET-1对L型Ca2+通道的作用相似,在1nM ET-1时,对照心肌细胞的峰值幅度为-3.26±0.8 nA,心力衰竭细胞中为-3.32±0.9 nA。心力衰竭细胞对ET-1收缩反应的减弱可能反映了由于循环中ET水平升高导致的ET受体脱敏,而跨膜Ca2+电导的改变并未体现这一点。因此,ET对心室心肌的作用可能涉及多种信号通路。